(S)-Mephenytoin: Gold-Standard CYP2C19 Substrate for Drug Metabolism

Executive Summary: (S)-Mephenytoin (SKU C3414, APExBIO) is a validated, high-purity small molecule substrate for cytochrome P450 2C19 (CYP2C19), supporting precise in vitro and organoid-based drug metabolism research [APExBIO product page]. It is metabolized via N-demethylation and 4-hydroxylation, providing specific readouts for CYP2C19 activity (Saito et al., 2025). The compound's kinetic properties have been rigorously defined (Km = 1.25 mM, Vmax = 0.8–1.25 nmol/min/nmol P450; in vitro with cytochrome b5). Its use as a CYP2C19 probe substrate is recommended for pharmacokinetic and enzyme polymorphism studies, particularly in advanced models such as human intestinal organoids. APExBIO ensures 98% purity and strict quality control for reproducible research outcomes.

Biological Rationale

The cytochrome P450 (CYP) enzyme family is central to the oxidative metabolism of xenobiotics and therapeutics. CYP2C19, also known as mephenytoin 4-hydroxylase, is responsible for the metabolism of a diverse range of drugs, including omeprazole, diazepam, and citalopram [1]. Genetic polymorphisms in CYP2C19 lead to significant interindividual variation in drug response and toxicity, making it a key target for personalized medicine approaches [2]. (S)-Mephenytoin is the prototypical probe substrate for CYP2C19, allowing researchers to quantify enzyme activity and investigate genetic variants in both clinical and preclinical settings. Standardized enzyme assays require substrates with defined kinetics and high specificity, properties exemplified by (S)-Mephenytoin.

Mechanism of Action of (S)-Mephenytoin

(S)-Mephenytoin, chemically (5S)-5-ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione, is metabolized primarily by CYP2C19 in human liver and intestinal tissues. The enzyme catalyzes stepwise N-demethylation and 4-hydroxylation on the aromatic ring, yielding measurable metabolites suitable for kinetic analyses [1]. In vitro, the presence of cytochrome b5 modulates the rate of 4-hydroxy metabolite formation. Reported kinetic parameters are Km = 1.25 mM and Vmax = 0.8–1.25 nmol/min/nmol P450 under standard buffer conditions (pH 7.4, 37°C). (S)-Mephenytoin does not significantly cross-react with other CYP isoforms, ensuring assay specificity. Its well-characterized metabolic pathway underlies its widespread use in enzyme phenotyping and drug-drug interaction studies [3].

Evidence & Benchmarks

• (S)-Mephenytoin is the reference CYP2C19 substrate in in vitro pharmacokinetic studies, supporting standardized kinetic assays (Saito et al., 2025, DOI).
• Km (Michaelis-Menten constant) for CYP2C19-mediated 4-hydroxylation of (S)-Mephenytoin is 1.25 mM (buffered at pH 7.4, 37°C; presence of cytochrome b5) (APExBIO).
• Vmax values range from 0.8–1.25 nmol 4-hydroxy product/min/nmol P450 enzyme (in vitro, human liver microsomes) (DOI).
• Human pluripotent stem cell-derived intestinal organoids express functional CYP2C19, enabling accurate (S)-Mephenytoin metabolism studies (Saito et al., 2025, DOI).
• 98% purity and validated solubility in DMSO (25 mg/ml), DMF (25 mg/ml), and ethanol (15 mg/ml) are ensured by APExBIO quality assurance (APExBIO).
• Species differences in CYP2C19 activity limit the translational value of animal models compared to hiPSC-derived intestinal organoids (DOI).
• Legacy models (e.g., Caco-2 cells) show low CYP2C19 expression, making (S)-Mephenytoin assays less reliable in such systems (DOI).

This article extends the detailed mechanistic focus of "(S)-Mephenytoin and the Next Era of CYP2C19 Drug Metaboli..." by providing updated kinetic parameters and highlighting the critical role of purity and storage in assay reproducibility.

For a concise summary of workflow best practices, see "(S)-Mephenytoin (SKU C3414): Reliable CYP2C19 Substrate S..."; this article adds structured evidence and clarifies integration limits with emerging organoid systems.

Applications, Limits & Misconceptions

(S)-Mephenytoin is widely used in:

• In vitro CYP2C19 activity assays (human liver microsomes, recombinant enzymes, hiPSC-derived intestinal organoids).
• Genetic polymorphism studies (identifying poor, intermediate, and extensive metabolizer phenotypes).
• Pharmacokinetic modeling of drug-drug interactions mediated by CYP2C19.
• Benchmarking new in vitro models against gold-standard metabolic pathways.

However, several practical and conceptual boundaries apply.

Common Pitfalls or Misconceptions

• (S)-Mephenytoin is not a substrate for CYP3A4, CYP2D6, or other major hepatic CYP isoforms; using it outside CYP2C19-specific assays may yield non-informative results.
• Legacy cell lines (e.g., Caco-2) may not reliably metabolize (S)-Mephenytoin due to low CYP2C19 expression.
• Animal models (e.g., rodent liver microsomes) may not accurately replicate human CYP2C19 kinetics due to species-specific differences (DOI).
• Long-term storage of (S)-Mephenytoin solutions is not recommended; stability declines at >-20°C or with repeated freeze-thaw cycles (APExBIO).
• This product is for research use only; it is not suitable for diagnostic or clinical therapeutic applications.

Workflow Integration & Parameters

For optimal results, (S)-Mephenytoin (C3414) from APExBIO should be dissolved in DMSO (up to 25 mg/ml), DMF (25 mg/ml), or ethanol (15 mg/ml) prior to use. All solutions must be prepared fresh and stored at -20°C; avoid repeated freeze-thaw cycles. For in vitro CYP2C19 assays, recommended concentrations are typically 0.5–2 mM, buffered at pH 7.4, with cytochrome b5 added as needed for maximal activity. Assay temperature should be 37°C with reaction times from 10–60 minutes, depending on the model. Human liver microsomes, recombinant CYP2C19, or hiPSC-derived intestinal organoids provide the highest translational relevance (Saito et al., 2025).

Shipping conditions require blue ice for small molecules. APExBIO ensures 98% purity and batch traceability. For detailed organoid workflows, refer to "(S)-Mephenytoin: Gold-Standard CYP2C19 Substrate in Organ...", which this article updates with new stability and kinetic benchmarks.

Conclusion & Outlook

(S)-Mephenytoin remains the gold-standard CYP2C19 substrate for translational drug metabolism research. Its use in advanced human-relevant models, such as hiPSC-derived intestinal organoids, enables accurate pharmacokinetic and genetic polymorphism studies. APExBIO (C3414) provides high-purity, rigorously validated material, supporting assay reproducibility and cross-laboratory comparability. Ongoing advances in organoid and stem cell technologies will further enhance the utility of (S)-Mephenytoin in dissecting human-specific drug metabolism pathways and optimizing personalized medicine approaches [1].